Login to Your Account

Partner Sankyo Halts Phase IIs; Metabasis Stock Takes Tumble

By Randall Osborne

Thursday, March 17, 2005
Metabasis Therapeutics Inc.'s overseas partner Sankyo Co. Ltd. pulled the plug on a pair of studies with CS-917, the glucose pathway inhibitor for diabetes, after two serious averse events apparently involving potentially fatal lactic acidosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription